U.S. markets closed

Zogenix, Inc. (ZGNX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
17.50-0.26 (-1.46%)
At close: 4:00PM EDT
Sign in to post a message.
  • S
    SAN
    A good company is what creates a value for you. Zogenix has the institution holding, has a good record but recent evaporation of its stock price has eroded all investors confidence. The bottom line is no matter how ambitious or pipeline is, it has to have the resilience.There are too many companies, on the other hand, like $6 but they haven’t dipped as much. People who invested with a lot of trust in this, see they being deceived. Hope somewhere the management sees this post to understand this sooner to curb this falling knife. I am sure patience has its limits and no matter what you do after a certain threshold things never come back or in the best case takes years. So Zogenix has to show the resilience and management has to work hard in either buying back or other capabilities to bring back the investor confidence. I can’t stress more on that.
  • S
    SAN
    Institutional buying has been active but the share price has been going down for past several weeks.How is that happening is what I am trying to understand. Can some one who is long, chime in please on the prospects of this. Thanks in advance.
  • e
    ed
    Holding this company has become a waste of time
    Only ones profiting are the insiders
  • D
    David
    Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet...
    Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet...
    www.globenewswire.com
    Bullish
  • 💊C
    Zogenix passed 3rd P3 trial in Dravet w usual 65% adjusted reduction. This one enables them to submit NDA in Japan.
  • 💊C
    The offering is more bond-like w a great 2.75% rate, but there is probably a future dilute coming. Q3 earnings may disappoint due to timing of the raise so hold on tight.
  • S
    SAN
    Pattern recognition: it will be stable for few days and all of a sudden drop drastically, locking in investors at lower levels. It dropped from $53 to 45 to 24 to 18. If you look at the graphs, it was $4 lower yesterday but never went up unlike other stocks and remained at that level only. Today, it has been hovering around 17.45.
  • D
    David
    https://finance.yahoo.com/news/hedge-funds-never-bullish-zogenix-163356456.html

    38 of the largest hedge funds are bullish on ZGNX. A record. 🚀
    Bullish
  • D
    David
    Zogenix initiated with a Market Perform at Raymond James Raymond James analyst Danielle Brill initiated coverage of Zogenix with a Market Perform rating. The analyst notes that the company's launch of Dravet Syndrome drug Fintepla comes at a "very inopportune time" given the COVID-19 related headwinds in addition to the competitive dynamic in DS and the drug's REMS requirements for new patients. Brill contends that near-term upside for Zogenix is limited.

    Read more at:
    https://thefly.com/n.php?id=3150703
    Raymond James initiates analyst coverage $55 PT
    Zogenix initiated with a Market Perform at Raymond James Raymond James ZGNX
    Zogenix initiated with a Market Perform at Raymond James Raymond James ZGNX
    thefly.com
    Bullish
  • D
    David
    Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
    Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
    seekingalpha.com
    Bullish
  • j
    jung
    I was looking to bottomfishing today but I just saw a block sale of almost 7mil shares @$17,55. I'm not sure if it's a good sign or a bad one so I cancelled my buy order.
  • D
    David
    To this end, the analyst puts an Outperform (i.e. Buy) rating and $65 price target on the stock. The implication for investors? Upside potential of 171%. (To watch Byrnes’ track record, click here)
    Bullish
  • 💊C
    This video gives an overview of Fintepla and Zogenix Central. Zogenix appears to have been very well prepared for launch. https://www.youtube.com/watch?v=Z476fM0dtsU&t=1s
    FINTEPLA overview and Zogenix Central Patient Services Program
    www.youtube.com
  • D
    David
    If that wasn’t enough, ZGNX’s management team is planning to discuss its sNDA submission for Lennox-Gastaut syndrome (LGS) with the FDA in September. “We anticipate sNDA filing for LGS in Q2 2021. We note that Study 1601 demonstrated that LGS patients treated with FINTEPLA achieved a statistically significant median reduction of 26.5% in monthly drop seizure frequency, p=0.0012,” Byrnes said.
    Bullish
  • D
    David
    Covering the stock for Northland, analyst Carl Byrnes tells clients that its FINTEPLA drug is “positioned to emerge as a breakthrough therapy for treating various forms of pediatric-onset epilepsy,” putting potential U.S. peak sales at roughly $2 billion.
    Bullish
  • 💊C
    Ovid failed LGS, at 20 weeks too. Their Dravet results are weaker than even Epidiolex.
  • D
    David
    Zogenix feeling bullish based upon physician feedback in July.
    Bullish
  • D
    David
    Bottom line: This stock is cheap because investors want to see revenue now. IMO in 6 months or less, it doubles or more from here. 83% efficacy compared to 39% at competitor. Revs will grow rapidly in 3rd quarter. LGS Snda meeting next month with FDA. EMA approval by Q4. Patience will be rewarded.
  • D
    David
    Expecting sales of Fintepla in Germany Q1 2021. 100% of all health care providers notified and educated. 450 physicians representing 80% of all DRAVET patients in communication with. Sales started last week 7/27. 230 REMS patients cleared.